Ga Syfovre denied as not FDA-approved for this use by Aetna?

Aetna's specific coverage criteria for ga syfovre are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Aetna Denies Syfovre as Not FDA-Approved — and How to Challenge It

A "not FDA-approved" denial for Syfovre (pegcetacoplan) is almost certainly a documentation or coding error. Syfovre holds FDA approval for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD). When this denial occurs, it typically means one of the following: the prior authorization request listed a diagnosis code that does not align with the FDA-approved indication; the drug name or NDC was entered incorrectly; or Aetna's system has not yet updated its drug file to reflect the current approval. In rare cases, the denial may be applied when the specific use being requested is off-label (e.g., a different indication).

## Why This Denial Is Appealable

If Syfovre is being requested for its FDA-approved indication of GA secondary to AMD, the "not FDA-approved" rationale is factually incorrect and must be reversed. Present the FDA approval directly. If the denial stems from a coding mismatch, a corrected prior authorization submission with the correct diagnosis code often resolves the issue without a formal appeal.

## Federal Appeal Rights

• ACA §2719 / ERISA §503: You are entitled to a full-and-fair review. A denial based on a factually incorrect premise — that an FDA-approved drug lacks approval — is reversible at internal review or, if necessary, external review.
• External Review: IROs are specifically empowered to review "not medically necessary" and "experimental" determinations; a "not FDA-approved" denial for an on-label use falls within this scope. The external review window is approximately four months from the final internal denial. Expedited review is available when delay poses health risk.

## Appeal Timeline

1. Confirm the exact denial reason in writing from Aetna. 2. Check the prior authorization submission for diagnosis code and drug code accuracy — a resubmission may resolve the issue faster than a formal appeal. 3. If a formal appeal is required, submit with the FDA label and prescriber attestation. 4. Escalate to external review if the internal appeal is denied.

## Documentation to Gather

• FDA prescribing information: A printed or downloaded copy of the current FDA-approved label for Syfovre, clearly showing the approved indication for GA secondary to AMD.
• Diagnosis confirmation: Retinal imaging confirming the GA diagnosis with the correct ICD-10 code used in the prior authorization request.
• Prescriber attestation letter: A letter from your retina specialist confirming that the requested use is on-label, citing the FDA approval date and indication, and attesting that the diagnosis matches the approved indication.
• Coding verification: Confirmation from the prescribing practice that the drug code, NDC, and diagnosis code submitted in the authorization request are correct.

## Criteria-Mapping Strategy

This appeal is straightforward: the denial premise is factually incorrect for an on-label use. Structure the appeal as (1) the denial reason stated by Aetna, (2) the FDA approval documentation contradicting it, (3) the diagnosis confirmation matching the approved indication, and (4) a request for immediate reversal. If Aetna's Clinical Policy Bulletin acknowledges the FDA approval but adds additional criteria, address those criteria as a secondary argument using the chart documentation and prescriber letter. Keep the primary argument simple: FDA-approved drug, FDA-approved indication, correct diagnosis.